Axiron is a popular topical medication used to treat low testosterone in men with hypogonadism. Like many other brands of testosterone, Axiron is the target of multiple lawsuits which claim the company knowingly put consumers at risk.
Axiron is approved to treat the medical condition, hypogonadism however, it has been prescribed to thousands of men to combat the natural signs of aging such as loss of muscle mass, decreased libido and fatigue. Testosterone manufacturers used compelling advertisements which promoted products for “Low-T”. Low-T is not a diagnosis but a marketing message and many men who used testosterone products like Axiron, were never tested for low testosterone levels.
They may have been placed at risk for serious adverse events including:
- Heart attack
- Blood clots
- Deep vein thrombosis
- Venous thromboembolism
- Pulmonary embolism
Many men who experienced serious side effects and family members of men who died after using testosterone replacement medications like Axiron, have filed lawsuits against Eli Lilly and other manufacturers.
Axiron FDA Warnings
Safety concerns arose when researchers published the results of two large studies which indicated that testosterone replacement may increase the risk of heart attack, stroke and other life-threatening events by two to three times that of men not taking testosterone. This prompted the Food and Drug Administration to issue a January 2014 warning announcement stating that they were investigating the safety of these products.
In June of 2014, a separate FDA warning was issued regarding testosterone’s increased risk of blood clotting episodes like deep vein thrombosis (DVT) and venous thromboembolism (VTE), which can lead to life-threatening events. The warning included a notice that labeling would be required to include clotting information and in mid-2015, the FDA required that labeling again be updated to include the potential risk of heart attack, stroke and other serious events.
Thousands of lawsuits have been filed against a number of testosterone product manufacturers. The majority of these cases were federal lawsuits that were consolidated into multidistrict litigation but in December of 2017, Eli Lilly announced that it was in the process of a settlement negotiation regarding multiple Axiron lawsuits.
Based on the negotiations, pending trial dates for Axiron lawsuits were set aside and though an agreement may have been reached, no details were publicly announced. In addition to the federal lawsuits that may have been settled, Lilly may still be facing other lawsuits in state and local courts and more may be expected.
Past medical injury lawsuits or settlements have provided compensation for medical costs, lost wages, pain and suffering or for wrongful death if the injury victim has died. Men or loved ones of those who suffered heart attack, stroke, pulmonary embolism or another life-threatening event while using Axiron should have their case evaluated by a legal expert.